UNSPSC 51124002: Disobutamide

This classification denotes an antiarrhythmic agent with the molecular formula C23H38ClN3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 4IZG3M7XVP, chemically known as 1-piperidinebutanamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)- but more generally known as disobutamide, which bears US NIH Compound Identifier 68566. European Medicines Agency schedules Disobutamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07234MIG.

UNSPSC 51124002 Disobutamide, a Commodity-tier code, covers pharmaceutical active pharmaceutical ingredients and finished medications supplied to state and local health systems, fire rescue services, and pharmacy benefit programs. State and local governments procure under this code primarily emergency medications for advanced life support, generic pharmaceuticals for state health agency formularies and employee health plans, and over-the-counter products distributed through institutional pharmacy networks. Recent solicitations show issuing bodies spanning municipal fire departments, state health agencies, and multi-state cooperative purchasing alliances managing inventory across dozens of participating jurisdictions. The City of Tampa Fire Rescue procured specific branded emergency medications (Labetalol, Epinephrine, Adenosine, Diltiazem) through a sealed bid with a small-local-business enterprise discount; the Texas Health and Human Services Commission is exploring direct-to-manufacturer pharmacy programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) manages generic and OTC pharmaceutical supply across state and local facilities in multiple states including Oregon through authorized pharmaceutical wholesalers.

Recent opportunities show concentrated activity in the Southwest and Upper Midwest. Tampa's IFB for Advanced Life Support Medications (due April 8, 2026) carried an estimated contract value of $40,000 with a one-year term and two one-year renewal options. Texas HHS's RFI on direct-to-manufacturer prescription programs (due April 3, 2026) represents early-stage market intelligence gathering with no award value specified, designed to inform later formal solicitation. MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) covers a two-year term with optional extensions, requiring vendors to maintain relationships with three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson—and to comply with current Good Manufacturing Practices, the Drug Supply Chain Security Act, and FDA requirements. Price competitiveness weighted 75 percent of MMCAP's evaluation, with vendors absorbing a 3 percent administrative fee on all purchases.